Live Breaking News & Updates on Managing Director Sharvil Patel
Stay updated with breaking news from Managing director sharvil patel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zydus will enter a competitive field, with an FDA decision on CymaBay s PBC drug due in August. Gilead Sciences announced its acquisition of CymaBay for $4.3 billion earlier in February. Saroglitazar, currently in a mid-to-late-stage trial for PBC, is also being tested for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease." ....
Saroglitazar Mg, approved by the DCGI, is an innovative drug from Zydus to treat chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato Hepatitis (NASH). ....
Lupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by India s DCGI for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lupin will have semi-exclusive rights to co-market the product in India under the brand name LINVAS. ....
(Bloomberg) After racing to build capacity and meet once seemingly insatiable orders for Covid-19 shots, the global vaccine industry is facing waning demand as many late-to-market producers fight over a slowing market. ....
Even as boosters are likely to keep demand alive for COVID-19 inoculations worldwide, the desperate shortages that existed for much of last year have waned. ....